Dynamic Technology Lab Private Ltd Purchases 11,127 Shares of ICU Medical, Inc. $ICUI

Key Points

• Dynamic Technology Lab Private Ltd increased its stake in ICU Medical, Inc. by 855.9%, acquiring an additional 11,127 shares during the first quarter, bringing its total ownership to 12,427 shares valued at approximately $1.7 million.
• Other significant investors, such as The Manufacturers Life Insurance Company and GAMMA Investing LLC, also dramatically increased their positions in ICU Medical, showcasing strong institutional interest.
• ICU Medical recently reported earnings of $2.10 per share for the latest quarter, exceeding estimates, but showed a year-over-year revenue decline of 8.0%.

Dynamic Technology Lab Private Ltd raised its position in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 855.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,427 shares of the medical instruments supplier's stock after buying an additional 11,127 shares during the quarter. Dynamic Technology Lab Private Ltd owned about 0.05% of ICU Medical worth $1,726,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC grew its stake in shares of ICU Medical by 27.2% during the 1st quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier's stock worth $99,000 after acquiring an additional 153 shares during the period. Blue Trust Inc. lifted its holdings in ICU Medical by 23.0% during the first quarter. Blue Trust Inc. now owns 801 shares of the medical instruments supplier's stock valued at $111,000 after purchasing an additional 150 shares during the last quarter. Vontobel Holding Ltd. bought a new position in ICU Medical during the first quarter worth about $235,000. Xponance Inc. boosted its position in ICU Medical by 5.3% during the first quarter. Xponance Inc. now owns 1,714 shares of the medical instruments supplier's stock worth $238,000 after purchasing an additional 86 shares during the period. Finally, Vident Advisory LLC purchased a new position in shares of ICU Medical in the first quarter worth about $270,000. Hedge funds and other institutional investors own 96.10% of the company's stock.

Insider Transactions at ICU Medical

In other ICU Medical news, CEO Vivek Jain acquired 21,929 shares of the business's stock in a transaction dated Thursday, August 14th. The stock was bought at an average price of $112.84 per share, with a total value of $2,474,468.36. Following the completion of the acquisition, the chief executive officer owned 130,149 shares of the company's stock, valued at $14,686,013.16. This trade represents a 20.26% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director David C. Greenberg acquired 1,200 shares of the firm's stock in a transaction that occurred on Wednesday, August 27th. The stock was bought at an average price of $126.42 per share, for a total transaction of $151,704.00. Following the completion of the transaction, the director owned 7,960 shares of the company's stock, valued at $1,006,303.20. The trade was a 17.75% increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.50% of the company's stock.

ICU Medical Price Performance

Shares of ICU Medical stock traded down $2.45 during trading on Friday, hitting $132.58. The stock had a trading volume of 102,137 shares, compared to its average volume of 267,972. The company has a current ratio of 2.44, a quick ratio of 1.17 and a debt-to-equity ratio of 0.63. ICU Medical, Inc. has a 12 month low of $107.00 and a 12 month high of $196.26. The firm has a market cap of $3.27 billion, a price-to-earnings ratio of -87.34 and a beta of 0.86. The business's 50-day moving average is $126.33 and its 200 day moving average is $134.02.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.44 by $0.66. The company had revenue of $543.57 million during the quarter, compared to analyst estimates of $543.33 million. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.The firm's quarterly revenue was down 8.0% on a year-over-year basis. During the same quarter last year, the company earned $1.56 earnings per share. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. As a group, sell-side analysts anticipate that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ICUI has been the topic of a number of recent research reports. Piper Sandler upped their price target on shares of ICU Medical from $145.00 to $153.00 and gave the company an "overweight" rating in a research note on Wednesday. Wall Street Zen raised shares of ICU Medical from a "hold" rating to a "buy" rating in a report on Friday, September 5th. Finally, Raymond James Financial dropped their target price on ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating on the stock in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, ICU Medical presently has an average rating of "Buy" and a consensus price target of $181.00.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.